A new formulation of erythromycin stearate: blood and sputum levels in patients with chronic lower respiratory tract infection

Abstract

Blood and sputum levels of erythromycin have been measured in six patients with chronic lower respiratory tract infection after treatment with a new formulation of erythromycin stearate (Abbott Laboratories; C946) in doses of 500 mg tds. Blood erythromycin levels were generally higher than those reported for other erythromycin preparations, but sputum levels were poor.